Amgen partners with Biocartis on diagnostic tests for cancer drug

You are here: Home > Central Coast Health Watch > Current Article

Amgen partners with Biocartis on diagnostic tests for cancer drug

By Staff Report / Monday, December 4th, 2017 / Comments Off on Amgen partners with Biocartis on diagnostic tests for cancer drug

Biotech giant Amgen signed an agreement with Belgium-based Biocartis Group to assist in the development of companion diagnostic tests for its colorectal cancer drug Vectibix. The Thousand Oaks-based company has partnered with Biocartis to develop its Idylla platform, which uses biomarkers to predict whether a treatment will be effective for a particular patient, since February…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.